A leading innovative biopharmaceutical company in China Media Reports Company News Menu Media Reports Company News Another Triumph in Tasly Biopharma Innovative Drug R&D — PCSK9 Monoclonal Antibody Approved for Clinical Trials Read More » Epidemic Prevention and Stable Production | Recording the 432 Hours of Sticking to the Post at the Production Workshop Read More » China's First Chronic Hepatitis B Drug T101 Approved to Enter Clinical Trials Successfully Completes the first subject Administration of Phase II Read More » Phase II Clinical Trial of Tasly Biopharma PUK (Recombinant Human Pro-urokinase for Injection) Thrombolysis for the Treatment of Acute Pulmonary Embolism Successfully Completes the Enrollment Read More » Tasly Biopharma’s Advanced Malignant Solid Tumors of Digestive Tract Drug T601 Successfully Completes the First Subject Administration of Phase I/IIa Clinical Trial Read More »
Another Triumph in Tasly Biopharma Innovative Drug R&D — PCSK9 Monoclonal Antibody Approved for Clinical Trials Read More »
Epidemic Prevention and Stable Production | Recording the 432 Hours of Sticking to the Post at the Production Workshop Read More »
China's First Chronic Hepatitis B Drug T101 Approved to Enter Clinical Trials Successfully Completes the first subject Administration of Phase II Read More »
Phase II Clinical Trial of Tasly Biopharma PUK (Recombinant Human Pro-urokinase for Injection) Thrombolysis for the Treatment of Acute Pulmonary Embolism Successfully Completes the Enrollment Read More »
Tasly Biopharma’s Advanced Malignant Solid Tumors of Digestive Tract Drug T601 Successfully Completes the First Subject Administration of Phase I/IIa Clinical Trial Read More »
